FDA Clears EOM Pharmaceuticals' IND for EOM613 in Cancer Cachexia, Phase 2 Trial Set for Q3 2026

The U.S. Food and Drug Administration cleared EOM Pharmaceuticals' investigational new drug application for EOM613, a peptide-based therapy for cancer cachexia. The decision enables the company to proceed with a planned Phase 2 clinical trial, scheduled to begin in the third quarter of 2026. Cancer cachexia is a severe wasting syndrome characterized by loss of muscle mass and fat, often complicating cancer treatment. No therapies are currently approved specifically for the condition. EOM613 aims to modulate immune and metabolic pathways to counteract this syndrome. EOM Pharmaceuticals has not yet announced specific trial sites or enrollment targets. Shares of the developmental-stage biotech may react to this regulatory milestone in upcoming trading sessions.